Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Jenkins

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Pharmaceutical Statistics|December 14, 2011
A statistician's perspective on biomarkers in drug developmentMartin Jenkins, Aiden Flynn, Trevor Smart, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 13, 2022
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOSMona Bafadhel, Klaus F Rabe, Fernando J Martinez, et al.
Advances in Therapy|April 30, 2021
Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysisArnaud Bourdin, Nicolas Molinari, Gary T Ferguson, et al.
Therapeutic Advances in Respiratory Disease|July 11, 2022
Predictive modeling of COPD exacerbation rates using baseline risk factorsDave Singh, John R Hurst, Fernando J Martinez, et al.
Respiratory Research|July 2, 2021
Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroidsMaarten van den Berge, Jan De Backer, Cedric Van Holsbeke, et al.
Respiratory Medicine|June 25, 2021
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trialFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 29, 2002
Tracking the ecological overshoot of the human economyMathis Wackernagel, Niels B Schulz, Diana Deumling, et al.
Canadian Respiratory Journal|December 18, 2010
The Christmas season as a risk factor for chronic obstructive pulmonary disease exacerbationsNeil W Johnston, Andrew McIvor, Kim Lambert, et al.
Respiratory Research|May 27, 2020
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studiesFernando J Martinez, Brian J Lipworth, Klaus F Rabe, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 15, 2018
A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPDWilfried De Backer, Jan De Backer, Wim Vos, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Pharmaceutical Statistics|December 14, 2011
A statistician's perspective on biomarkers in drug developmentMartin Jenkins, Aiden Flynn, Trevor Smart, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 13, 2022
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOSMona Bafadhel, Klaus F Rabe, Fernando J Martinez, et al.
Advances in Therapy|April 30, 2021
Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysisArnaud Bourdin, Nicolas Molinari, Gary T Ferguson, et al.
Therapeutic Advances in Respiratory Disease|July 11, 2022
Predictive modeling of COPD exacerbation rates using baseline risk factorsDave Singh, John R Hurst, Fernando J Martinez, et al.
Respiratory Research|July 2, 2021
Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroidsMaarten van den Berge, Jan De Backer, Cedric Van Holsbeke, et al.
Respiratory Medicine|June 25, 2021
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trialFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 29, 2002
Tracking the ecological overshoot of the human economyMathis Wackernagel, Niels B Schulz, Diana Deumling, et al.
Canadian Respiratory Journal|December 18, 2010
The Christmas season as a risk factor for chronic obstructive pulmonary disease exacerbationsNeil W Johnston, Andrew McIvor, Kim Lambert, et al.
Respiratory Research|May 27, 2020
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studiesFernando J Martinez, Brian J Lipworth, Klaus F Rabe, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 15, 2018
A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPDWilfried De Backer, Jan De Backer, Wim Vos, et al.
Pageof 4